Approved Drug May Be Repurposed to Treat Tumors Resulting from NF2-Related Schwannomatosis
Mass General-led phase 2 clinical trial generates promising results for brigatinib as a treatment for the genetic condition, which is characterized by brain and nerve sheath tumors.
There is not much more I can say. In the many years I have met with Dr. Plotkin and his staff have been wonderful. Thank you to everyone I deal with at MGH.
Dr. Plotkin is the best! He's kind, concerned and knowledgeable. While waiting for my MRI results is stressful, it's been a pleasure togo over them with him for the past 11 years.
Dr. Plotkin and [redacted] and others on the team have always been thorough in their examinations, deliberate in making sure I understood the issues in my care, and willing to give non-judgmental guidance in my decisions.
Very friendly and easy to talk to just a down to earth doctor
Reassuring.
I am grateful for my life, Dr. Plotkin has been with me on the journey.
Dr.Plotkin has been my neurologist for a very long time. His entire staff from the front desk,MA's, RN's and NP's always treats patients with the upmost respect,and compassion.
Dr Plotkin is very caring, sensitive and knowledgeable with [redacted] diagnosis. We feel she is getting the best care possible with Dr Plotkin's help and expertise.
Have come to this clinic for 30+ years. In the office is exactly what I need. But outside the office (at home, messages, emails, questions, planning, communication...) are very very difficult
Thank you for being my doctor [redacted]